Neurophysiology and Biomechanics of Urethra in Stress Urinary Incontinence

压力性尿失禁尿道的神经生理学和生物力学

基本信息

  • 批准号:
    7228532
  • 负责人:
  • 金额:
    $ 32.8万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2004
  • 资助国家:
    美国
  • 起止时间:
    2004-04-01 至 2009-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Stress urinary incontinence (SUI) is defined as involuntary loss of urine secondary to an increase in abdominal pressure during events such as sneezing, coughing or laughing in the absence of bladder contractions. This disorder is a significant gynecological/urological problem currently affecting approximately 25 million American women. These SUI patients exhibit the high incidence of intrinsic sphincter deficiency, characterized by a malfunction of the urethral sphincter mechanism resulting in the low-pressure urethra. However, normal physiology and pathophysiology of the urethral continence mechanism in relation to SUI are not well elucidated. Thus, utilizing both in-vivo and ex-vivo techniques developed in our laboratory, we propose to perform systematic analyses of urethral continence mechanisms under stress conditions. First, in-vivo neurophysiological analyses will be performed in normal animals and animal models of SUI. Next, ex-vivo biomechanical analyses will be performed of the normal and SUI urethra. Finally, based on these results, we will also seek to explore potential pharmacotherapies of SUI. In this proposal, we hypothesize: 1) the detailed neurophysiological and biomechanical properties contributing to normal urethral continence mechanisms at different positions along the urethra can be identified in normal rats, 2) pathological changes in neurophysiological and biomechanical properties of urethral continence mechanisms can be identified in two different animals models of SUI, and 3) pharmacological treatments using serotonine/norepinephrine reuptake inhibitors and/or adrenoceptor agonists can improve urethral continence mechanisms in two animal models of SUL The Specific Aims of this grant are: I) to characterize the normal physiological and biomechanical properties of the urethral closure mechanisms in normal animals using: a) microtip transducer catheters to measure bladder and urethral responses in-vivo during sneezing or passive increases in intravesical pressure, b) in-vivo leak point pressure measurements during sneezing or passive increases in intravesical pressure, and c) ex-vivo whole urethra biomechanical studies; II) to investigate the pathological changes in the above measurements in two rat models of SUI (vaginal over distension or transection of the nerves to external urethral sphincter and pelvic floor muscles); and III) to investigate possible pharmacotherapies for improving the urethral closure mechanism in the two rat models of SUI. By defining the detailed urethral pathology of SUI, we can offer the hope of prevention and reversal of this potentially devastating condition. This is recognized as a high priority in the urologic/gynecologic care of SUI patients.
描述(申请人提供):压力性尿失禁(SUI)被定义为在没有膀胱收缩的情况下,在打喷嚏、咳嗽或大笑等事件中继发于腹压增加而导致的非自愿尿失禁。这种疾病是一个严重的妇科/泌尿科问题,目前影响着大约2500万美国妇女。这些SUI患者表现出固有括约肌缺陷的高发生率,其特征是尿道括约肌机制故障导致尿路低压。然而,与SUI相关的正常生理学和病理生理学关于尿路失禁的机制还没有很好的阐明。因此,利用我们实验室开发的体内和体外技术,我们建议对应激条件下的尿路控制机制进行系统的分析。首先,将在正常动物和SUI动物模型中进行体内神经生理学分析。接下来,我们将对正常和SUI的尿路进行体外生物力学分析。最后,基于这些结果,我们还将寻求SUI潜在的药物治疗方法。在这个方案中,我们假设:1)在正常大鼠的尿路不同位置,可以确定与正常尿路控制机制有关的详细的神经生理和生物力学特性;2)在两种不同的SUI动物模型中,可以确定尿路可控机制的神经生理和生物力学特性的病理变化,3)使用5-羟色胺/去甲肾上腺素再摄取抑制剂和/或肾上腺素能受体激动剂的药物治疗可以改善SUL两种动物模型的尿路控制机制。这项资助的具体目的是:1)研究正常动物尿路关闭机制的正常生理和生物力学特性:a)微尖换能器导管用于测量打喷嚏或膀胱内压力被动升高时体内的膀胱和尿路反应,b)体内打喷嚏或膀胱内压力被动升高时漏点压力的测量,以及c)体外整体尿路生物力学研究;Ii)研究两种SUI模型(阴道过度扩张或切断支配外括约肌和盆底肌的神经)上述指标的病理变化;iii)探讨改善两种SUI模型大鼠尿路闭合机制的可能药物疗法。通过明确SUI的详细的尿路病理,我们可以提供预防和逆转这种潜在的破坏性疾病的希望。这在SUI患者的泌尿/妇科护理中被认为是高度优先的。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

NAOKI YOSHIMURA其他文献

NAOKI YOSHIMURA的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('NAOKI YOSHIMURA', 18)}}的其他基金

Afferent and urothelial plasticity underlying bladder sensitization in prostatic inflammation
前列腺炎症中膀胱敏感的传入和尿路上皮可塑性
  • 批准号:
    10002343
  • 财政年份:
    2016
  • 资助金额:
    $ 32.8万
  • 项目类别:
GENE THERAPY FOR BLADDER PAIN
膀胱疼痛的基因疗法
  • 批准号:
    7083039
  • 财政年份:
    2006
  • 资助金额:
    $ 32.8万
  • 项目类别:
Neurophysiology and Biomechanics of Urethra in SUI
SUI 尿道的神经生理学和生物力学
  • 批准号:
    6761522
  • 财政年份:
    2004
  • 资助金额:
    $ 32.8万
  • 项目类别:
Neurophysiology and Biomechanics of Urethra in SUI
SUI 尿道的神经生理学和生物力学
  • 批准号:
    6868207
  • 财政年份:
    2004
  • 资助金额:
    $ 32.8万
  • 项目类别:
Afferent modulation in bladde dysfunction
叶片功能障碍的传入调节
  • 批准号:
    6840813
  • 财政年份:
    2004
  • 资助金额:
    $ 32.8万
  • 项目类别:
Afferent modulation in bladder dysfunction
膀胱功能障碍的传入调节
  • 批准号:
    6821271
  • 财政年份:
    2004
  • 资助金额:
    $ 32.8万
  • 项目类别:
Afferent modulation in bladde dysfunction
叶片功能障碍的传入调节
  • 批准号:
    7163050
  • 财政年份:
    2004
  • 资助金额:
    $ 32.8万
  • 项目类别:
Neurophysiology and Biomechanics of Urethra in Stress Urinary Incontinence
压力性尿失禁尿道的神经生理学和生物力学
  • 批准号:
    7395042
  • 财政年份:
    2004
  • 资助金额:
    $ 32.8万
  • 项目类别:
Neurophysiology and Biomechanics of Urethra in SUI
SUI 尿道的神经生理学和生物力学
  • 批准号:
    7054143
  • 财政年份:
    2004
  • 资助金额:
    $ 32.8万
  • 项目类别:
Afferent modulation in bladde dysfunction
叶片功能障碍的传入调节
  • 批准号:
    7002754
  • 财政年份:
    2004
  • 资助金额:
    $ 32.8万
  • 项目类别:

相似海外基金

EFFECTS OF BETA ADRENERGIC ANTAGONISTS
β 肾上腺素能拮抗剂的作用
  • 批准号:
    6248122
  • 财政年份:
    1997
  • 资助金额:
    $ 32.8万
  • 项目类别:
GLAUCOMA AND ALPHA ADRENERGIC ANTAGONISTS
青光眼和α肾上腺素能拮抗剂
  • 批准号:
    3261472
  • 财政年份:
    1985
  • 资助金额:
    $ 32.8万
  • 项目类别:
SELECTIVE ADRENERGIC ANTAGONISTS & INTRAOCULAR PRESSURE
选择性肾上腺素能拮抗剂
  • 批准号:
    3038642
  • 财政年份:
    1985
  • 资助金额:
    $ 32.8万
  • 项目类别:
GLAUCOMA AND ALPHA ADRENERGIC ANTAGONISTS
青光眼和α肾上腺素能拮抗剂
  • 批准号:
    3261474
  • 财政年份:
    1985
  • 资助金额:
    $ 32.8万
  • 项目类别:
GLAUCOMA AND ALPHA ADRENERGIC ANTAGONISTS
青光眼和α肾上腺素能拮抗剂
  • 批准号:
    3261475
  • 财政年份:
    1985
  • 资助金额:
    $ 32.8万
  • 项目类别:
GLAUCOMA AND ALPHA ADRENERGIC ANTAGONISTS
青光眼和α肾上腺素能拮抗剂
  • 批准号:
    3261473
  • 财政年份:
    1985
  • 资助金额:
    $ 32.8万
  • 项目类别:
GLAUCOMA AND ALPHA ADRENERGIC ANTAGONISTS
青光眼和α肾上腺素能拮抗剂
  • 批准号:
    3261476
  • 财政年份:
    1985
  • 资助金额:
    $ 32.8万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了